Hyloris Pharmaceuticals (XBRU:HYL) Debt-to-Equity : 0.05 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Hyloris Pharmaceuticals Debt-to-Equity?

Hyloris Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.24 Mil. Hyloris Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €1.51 Mil. Hyloris Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €38.82 Mil. Hyloris Pharmaceuticals's debt to equity for the quarter that ended in Dec. 2023 was 0.05.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Hyloris Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

XBRU:HYL' s Debt-to-Equity Range Over the Past 10 Years
Min: -4.17 Med: -0.57 Max: 0.14
Current: 0.05

During the past 8 years, the highest Debt-to-Equity Ratio of Hyloris Pharmaceuticals was 0.14. The lowest was -4.17. And the median was -0.57.

XBRU:HYL's Debt-to-Equity is ranked better than
73% of 1074 companies
in the Biotechnology industry
Industry Median: 0.15 vs XBRU:HYL: 0.05

Hyloris Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Hyloris Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hyloris Pharmaceuticals Debt-to-Equity Chart

Hyloris Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

-1.30

0.14

0.02

0.05

Hyloris Pharmaceuticals Semi-Annual Data
	Dec17	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial							-	-	0.02	0.03	0.05

Competitive Comparison of Hyloris Pharmaceuticals's Debt-to-Equity

For the Biotechnology subindustry, Hyloris Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hyloris Pharmaceuticals's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hyloris Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Hyloris Pharmaceuticals's Debt-to-Equity falls into.

Hyloris Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Hyloris Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.241	+	1.51)	/	38.822
	=	0.05

Hyloris Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.241	+	1.51)	/	38.822
	=	0.05

Hyloris Pharmaceuticals (XBRU:HYL) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Hyloris Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Hyloris Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Hyloris Pharmaceuticals (XBRU:HYL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hyloris Pharmaceuticals SA (XBRU:HYL) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

52U:Germany

Address

Boulevard Patience et Beaujonc N°3/1, Liege, BEL, 4000

Website

https://www.hyloris.com

Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans these areas such as Cardiovascular, Other Reformulations, and Established markets (high-barrier generics). It has two early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic IV, a non-opioid analgesic product for the treatment of pain.